BiotechTube
Pilatus Biosciences

Pilatus Biosciences

Zurich, Switzerland· Est.
pilatusbio.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Pilatus Biosciences is a private, preclinical-stage biotech leveraging immunometabolism to develop novel cancer therapies. Its lead asset, PLT012, an anti-CD36 metabolic checkpoint antibody, has secured FDA Orphan Drug and Fast Track designations for hepatocellular carcinoma and is advancing into Phase 1 trials. The company, spun out from research at the Ludwig Institute for Cancer Research and University of Lausanne, is actively seeking partnerships and investment to advance its pipeline.

OncologyImmune-related Diseases

Technology Platform

Discovery and development of first-in-class antibodies and bifunctional proteins targeting metabolic checkpoints to reprogram the immunosuppressive microenvironment in cancer and inflammatory diseases.

Opportunities

The company is targeting large unmet needs in oncology, particularly in liver cancers, with a novel immunometabolism approach that could overcome resistance to current therapies.
Regulatory designations (Orphan Drug, Fast Track) enhance development incentives and commercial potential.
The growing field of metabolic immunotherapy presents significant partnership interest from larger pharmaceutical companies.

Risk Factors

High clinical risk associated with a first-in-class mechanism; safety and efficacy in humans are unproven.
Intense competition in the immuno-oncology and emerging immunometabolism space from well-funded competitors.
Dependence on raising additional capital to fund operations and clinical trials in a challenging financing environment.

Competitive Landscape

Pilatus operates in the competitive immuno-oncology space, specifically within the emerging niche of metabolic checkpoint inhibitors. It faces competition from other biotechs and large pharma companies developing therapies targeting metabolic pathways like IDO, ARG1, CD73, and CD36. Its differentiation lies in its specific anti-CD36 antibody approach and its foundational research from prestigious Swiss institutions.

More companies in Immunotherapy / Immuno-Oncology →More companies in Switzerland →